Mercado de reactivos y equipos de transfección en América del Norte: tendencias de la industria y pronóstico hasta 2030

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado de reactivos y equipos de transfección en América del Norte: tendencias de la industria y pronóstico hasta 2030

  • Medical Devices
  • Published Report
  • Mar 2023
  • North America
  • 350 Páginas
  • Número de tablas: 45
  • Número de figuras: 57

North America Transfection Reagents And Equipment Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2023 –2030
Diagram Tamaño del mercado (año base)
MILLONES DE DÓLARES
Diagram Tamaño del mercado (año de pronóstico)
MILLONES DE DÓLARES
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Mercado de reactivos y equipos de transfección de América del Norte, por productos (reactivos, kits e instrumentos), etapa (investigación, preclínica, fases clínicas y comercial), tipo (reactivos y equipos de transfección transitoria, reactivos y equipos de transfección estable), métodos (métodos no virales y métodos virales), tipos de moléculas (ADN plasmídico, ARN interferente pequeño (siRNA), proteínas, oligonucleótidos de ADN, complejos de ribonucleoproteína (RNP) y otros), organismo (células de mamíferos, plantas, hongos, virus y bacterias), aplicación (aplicación in vitro, aplicación in vivo, bioproducción y otras), usuario final (biofarmacia, CRO, (CMO/CDMO), academia, hospitales, laboratorios clínicos y otros), canal de distribución (licitación directa, ventas minoristas y otros), tendencias de la industria y pronóstico hasta 2030

Mercado de reactivos y equipos de transfección de América del Norte

Análisis y perspectivas del mercado de reactivos y equipos de transfección de América del Norte

La transfección implica la introducción de ácidos nucleicos en células eucariotas mediante métodos virales y no virales. El método de transfección puede superar el desafío de transferir la membrana cargada negativamente. Los productos químicos como el fosfato de calcio y el dietilaminoetil (DEAE) -dextrano o el reactivo basado en lípidos catiónicos reaccionan con la capa externa de ADN. Neutralizan la carga negativa general, imparten la cantidad positiva a la molécula y, por lo tanto, permiten la administración de ADN. Los métodos físicos como la electroporación crean poros diminutos en la membrana celular mediante la aplicación de voltaje eléctrico, lo que permite la entrada de ADN directamente al citoplasma. El DEAE-dextrano se utiliza para la transfección transitoria; sin embargo, la lipofección puede lograr una transfección estable y, por lo tanto, puede usarse para la expresión de proteínas a largo plazo. La transfección mediada por fosfato de calcio también se puede utilizar para la transfección estable. El método de transfección viral logra una alta eficiencia y se utiliza para varias fases del desarrollo de productos farmacéuticos.

Mercado de reactivos y equipos de transfección de América del Norte

Mercado de reactivos y equipos de transfección de América del Norte

El método de transfección se utiliza para varias aplicaciones relacionadas con la agricultura, para la protección de cultivos y la mejora del rendimiento, para la producción de productos de biología sintética para mejorar los sabores y las fragancias, y para mejorar las proteínas unicelulares, entre otras. La demanda de transfección ha aumentado tanto en los países desarrollados como en los países en desarrollo, y la razón detrás de esto es la creciente incidencia de enfermedades crónicas. El mercado de la transfección está creciendo debido a la creciente demanda de genes quiméricos y la utilización de productos biofarmacéuticos en la producción de proteínas. El mercado crecerá en el período de pronóstico debido a la exploración de mercados emergentes, iniciativas estratégicas de los actores del mercado y un creciente apoyo gubernamental.

Se espera que el alto costo de los instrumentos, la efectividad selectiva del reactivo de transfección y el daño celular inducido por los métodos de transfección limiten el crecimiento del mercado de reactivos y equipos de transfección en América del Norte.

The market is growing due to several strategic initiatives adopted by market players involving acquisition, collaboration, and partnership.

Data Bridge Market Research analyzes that the North America transfection reagent and equipment market is expected to reach the value of USD 1,319,255.58 thousand by 2030, at a CAGR of 9.9% during the forecast period.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2020-2016)

Quantitative Units

Revenue in Thousand, Volumes in Units, Pricing in USD

Segments Covered

By Products (Reagent & Kits and Instruments), Stage (Research, Preclinical, Clinical Phases, and Commercial), Type (Transient Transfection Reagent and Equipment, Stable Transfection Reagent, and Equipment), Methods (Non-viral Methods and Viral Methods), Types of Molecule (Plasmid DNA, Small Interfering RNA (siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes (RNPs), and Others), Organism (Mammalian Cells, Plants, Fungi, Virus, and Bacteria), Application (In Vitro Application, In Vivo Application, Bioproduction and Others), End User (Biopharma, CROs, (CMOs/CDMOs), Academia, Hospitals, Clinical Labs, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others).

Countries Covered

U.S., Canada, and Mexico.

Market Players Covered

Some of the major players operating in this market are Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific (A Subsidiary of FUJIFILM Holdings Corporation), Avanti Polar Lipids (A Subsidiary of  Croda International Plc),  PerkinElmer chemagen Technologie GmbH (A Subsidiary of  PerkinElmer Inc.), Cytiva, Geno Technology Inc., USA, R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc. (A Subsidiary of F. Hoffmann-La Roche Ltd), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc. (abm), Beckman Coulter, Inc. (A Subsidiary of Danaher), Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc., and Twist Bioscience, among others.

Market Definition

The transfection method is used to introduce RNA, DNA or protein products in cells to alter the phenotype and genotype of the organism. The transfection method involves the new gene transfer or transferring a gene construct such as Clustered regularly interspaced short palindromic repeats (CRISPR) for genome editing purposes. Transfection has wide applications in th  e field of immunotherapy, gene therapy, and cell therapy, among others. Transfection involves both non-viral and viral-mediated transfection. The chemical and physical methods can achieve non–viral transfection. The most common chemical method used for transfection is calcium phosphate transfection, and liposome transfection, among others. Viral transfection yields high transfection efficiencies, and various types of physical methods employed for transfection include microinjection, biolistic particle delivery, and electroporation, among which electroporation provides high transfection efficiency. Transfection is of two types either it can be transient or stable transfection. For short-term gene expression studies such as gene knock-out studies, small-scale production transient transfection method is preferred; however, long-term research studies and large-scale protein production stable transfection methods are widely adopted.

North America Transfection Reagent and Equipment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • RISE IN THE PREVALENCE OF CHRONIC DISEASES

The prevalence of chronic diseases is increasing worldwide, leading to the demand for effective and accurate treatment. Transfection is used to deliver targeted modified genes to treat several genetic diseases. The transfection method is also used for the delivery of the CRISPR gene, which can enhance adaptive immunity and prevent an individual from different diseases.

The increasing cases of chronic diseases such as COVID-19 and other infectious diseases have led to the discovery of effective gene therapy products which can replace the defective gene with the correct gene. The transfection method is widely used for gene therapy, among others. As the demand for effective and accurate treatment is increasing worldwide, the demand for gene therapy and transfection method is also increasing. Moreover, several undergoing researches proving gene therapy to have the potential for chronic disease treatment are also increasing its demand among physicians and patients. This thus signifies that the rise in chronic disease prevalence is acting as a driver for the North America transfection Reagent and equipment market growth.

  • DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

Synthetic biology is a new era of biology that incorporates the engineering principle into biology. Synthetic biology involves the chemical synthesis of DNA by combining the knowledge of genomics to reassemble the DNA genomes. The synthetic biology that sequences into the new genes involves genetic engineering, which incorporates the transfection method, among others. As the demand for synthetic biology products is increasing worldwide, the use of transfection products is also increasing.

The demand for synthetic biology products is increasing due to the increasing demand for effective and innovative products. The manufacturing of synthetic products enhances the demand for transfection products, as gene transfer can be accompanied by the transfection method, among others. Thus, this signifies that synthetic product development drives the North America transfection Reagent and equipment market growth.

Restraint

  • CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

Some transfection methods have been reported to cause cell damage, reducing the reproducibility of the overall method. Among the several kinds of transfection procedures, electroporation has been reported to cause maximum cell damage as per the increase in voltage. This cell damage lowers the efficiency rate and impacts the ongoing project.

One of the most common side effects of the transfection procedure is cell damage which lowers the cells metabolic events and leads to cell death. This damaged cell can enhance the media toxicity and hence produces inappropriate results. Thus, this suggests that cell damage induced by the transfection procedure acts as a restraint for the North America transfection Reagent and equipment market growth.

Opportunity

  • EXPLORATION OF EMERGING MARKET

The transfection products have been shown as promising tools for the genetic engineering and proteomic industry. The top market for transfection products is in Europe and North America. By looking at the positive outcomes of these products, many market players are penetrating their roots in growing economies involving China and India, among others. The emerging market allows these market players to combat the loss that arises from the well-established market.

As emerging markets allow the market players to overcome the economic downturn specified to particular established markets, investment and exploration of emerging markets allow the market players to engage in the development and manufacturing of transfection products to attain lucrative growth. Thus, this signifies that exploring emerging markets is an opportunity to grow the North America transfection Reagent and equipment market.

Challenge

  • LONG APPROVAL PROCEDURE

The long approval procedure for transfection reagents and instruments is a hindering agent for the growth of the transfection market. Transfection products are subjected to extensive regulations and have to monitor every time. The transfection products are widely used for the insertion of desired gene molecules in a particular cell line to obtain proteins and other biological compounds. This process is thus investigated and approved by the long and strict regulatory procedures. The long process required to get a positive result from every conducted clinical trial led to more time consumption and the investment of lots of money by market players.

The transfection Reagent are mostly subjected to 21CFR parts 210 and 211 U.S. FDA guidelines, according to which the manufacturers had to assure that the reagent manufactured meets the safety, packaging and processing characteristics proposed by the regulatory agencies. The owner or manufacturer has to submit licenses under section 351 of the PHS (Public Health Services) Act, which is quite a tedious procedure. Thus, this signifies that long approval procedures challenge the North America transfection Reagent and equipment market growth.

Recent Developments

  • In August 2021, Mirus Bio expanded the TransIT VirusGen platform for Good Manufacturing Practice (GMP) viral vector production to support cell and gene therapy development, process operations, and commercial production. The extension, referred to as TransIT VirusGen GMP Transfection Reagent, is designed to improve the packaging and delivery of vector DNA to suspension and adherent HEK 293 cell types to improve the production of recombinant adeno-associated viruses and lentiviral vectors.
  • In April 2021, BOC Sciences announced the launch of two in vivo RNA transfection kits, namely siRNA in vivo transfection kits and mRNA in vivo transfection kits, suitable for in vivo transfection of siRNA and mRNA, respectively.

North America Transfection Reagent and Equipment Market Scope

North America transfection Reagent and equipment market is segmented into nine notable segments such as products, stage, methods, type, types of molecule, application, end user, organism, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

PRODUCTS

  • INSTRUMENTS
  • REAGENT & KITS

On the basis of products, the North America transfection reagent and equipment market is segmented into instruments and reagent & kits.

STAGE

  • RESEARCH
  • PRECLINICAL
  • CLINICAL PHASES
  • COMMERCIAL

On the basis of stage, the North America transfection reagent and equipment market is segmented into research, preclinical, clinical phases and commercial.

TYPE

  • TRANSIENT TRANSFECTION REAGENT AND EQUIPMENT
  • STABLE TRANSFECTION REAGENT AND EQUIPMENT

Sobre la base del tipo, el mercado de reactivos y equipos de transfección de América del Norte está segmentado en reactivos y equipos de transfección transitoria y reactivos y equipos de transfección estable.

MÉTODOS

  • MÉTODOS NO VIRALES
  • MÉTODOS VIRALES

Sobre la base de los métodos, el mercado de reactivos y equipos de transfección de América del Norte está segmentado en métodos no virales y métodos virales.

TIPOS DE MOLÉCULAS

  • ADN PLASMÍDICO
  • Oligonucleótidos del ADN
  • ARN DE INTERFERENCIA PEQUEÑO (ARNIP)
  • PROTEÍNAS
  • COMPLEJOS DE RIBONUCLEOPROTEÍNAS (RNPS)
  • OTROS

Sobre la base de los tipos de moléculas, el mercado de reactivos y equipos de transfección de América del Norte está segmentado en ADN plasmídico, oligonucleótidos de ADN, ARN interferente pequeño (siRNA), proteínas, complejos de ribonucleoproteínas (RNP) y otros.

ORGANISMO

  • BACTERIAS
  • CÉLULAS DE MAMÍFEROS
  • HONGOS
  • PLANTAS
  • VIRUS

Sobre la base del organismo, el mercado de reactivos y equipos de transfección de América del Norte está segmentado en bacterias, células de mamíferos, hongos, plantas y virus.

SOLICITUD

  • POR TIPO
    • APLICACIÓN IN VITRO
    • APLICACIÓN IN VIVO
    • BIOPRODUCCIÓN
    • OTROS
  • POR INDUSTRIA
    • AGRICULTURA
    • BIOLOGÍA SINTÉTICA
    • OTROS

Sobre la base de la aplicación, el mercado de reactivos y equipos de transfección de América del Norte está segmentado por tipo en aplicación in vitro, aplicación in vivo, bioproducción, otros, y por industria en agricultura, biología sintética, otros.

USUARIO FINAL

  • BIOFARMACIA
  • Cruz
  • CMOS/CDMOS
  • ACADEMIA
  • HOSPITALES
  • LABORATORIOS CLÍNICOS
  • OTROS

Sobre la base del usuario final, el mercado de reactivos y equipos de transfección de América del Norte está segmentado en biofarmacia, CRO, CMO/CDMO, academia, hospitales, laboratorios clínicos y otros.

CANAL DE DISTRIBUCIÓN

  • LICITACIÓN DIRECTA
  • VENTAS AL POR MENOR
  • OTROS

Sobre la base del canal de distribución, el mercado de reactivos y equipos de transfección de América del Norte está segmentado en licitación directa, ventas minoristas y otros.

Análisis y perspectivas regionales del mercado de reactivos y equipos de transfección de América del Norte

El mercado de reactivos y equipos de transfección de América del Norte se clasifica en muchos segmentos notables, como geografía, productos, etapas, métodos, tipo, tipos de moléculas, aplicación, usuario final, organismo y canal de distribución.

Los países cubiertos en este informe de mercado son Estados Unidos, Canadá y México.

En 2023, América del Norte dominará debido a la presencia de actores clave del mercado en el mercado de consumo más grande con un PIB alto. Se espera que EE. UU. crezca debido al aumento en la prevalencia de enfermedades crónicas y raras que conducen al aumento en el uso de reactivos y equipos de transfección.

Norteamérica domina el mercado debido a que se espera que la creciente inversión en atención médica impulse el crecimiento del mercado. Estados Unidos domina la región de Norteamérica debido a la fuerte presencia de actores clave.

La sección de países del informe también proporciona factores de impacto individuales en el mercado y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, se consideran la presencia y disponibilidad de marcas de América del Norte y los desafíos que enfrentan debido a la competencia grande o escasa de las marcas locales y nacionales, y el impacto de los canales de venta al proporcionar un análisis de pronóstico de los datos del país.

Análisis del panorama competitivo y de la cuota de mercado de reactivos y equipos de transfección en América del Norte

El panorama competitivo del mercado de reactivos y equipos de transfección de América del Norte proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las aprobaciones de productos, la amplitud y el alcance de los productos, el dominio de las aplicaciones y la curva de vida del tipo de producto. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa en el mercado de reactivos y equipos de transfección de América del Norte.

Algunos de los principales actores que operan en este mercado son Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific (una subsidiaria de FUJIFILM Holdings Corporation), Avanti Polar Lipids (una subsidiaria de Croda International Plc), PerkinElmer chemagen Technologie GmbH (una subsidiaria de PerkinElmer Inc.), Cytiva, Geno Technology Inc., EE. UU., R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc. (una subsidiaria de F. Hoffmann-La Roche Ltd), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc. (abm), Beckman Coulter, Inc. (una subsidiaria de Danaher), Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc. y Twist Bioscience, entre otros.


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 INDUSTRY INSIGHTS:

6 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, REGULATIONS

6.1 EUROPEAN UNION REGULATORY SCENARIO

6.2 U.S. REGULATORY SCENARIO

6.3 JAPAN REGULATORY SCENARIO

6.4 CHINA REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES

7.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

7.1.3 GROWING DEMAND FOR CHIMERIC GENES

7.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH

7.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS

7.2 RESTRAINTS

7.2.1 HIGH COST OF TRANSFECTION PRODUCTS

7.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS

7.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

7.3 OPPORTUNITIES

7.3.1 EXPLORATION OF EMERGING MARKET

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.3 SURGING LEVEL OF INVESTMENT

7.4 CHALLENGES

7.4.1 LONG APPROVAL PROCEDURE

7.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS-ASSOCIATED TRANSFECTION

7.4.3 LACK OF TRAINED PROFESSIONALS

8 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS

8.1 OVERVIEW

8.2 REAGENTS & KITS

8.3 INSTRUMENTS

9 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE

9.1 OVERVIEW

9.2 RESEARCH

9.3 PRECLINICAL

9.4 CLINICAL PHASES

9.5 COMMERCIAL

10 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT

10.3 STABLE TRANSECTION REAGENTS AND EQUIPMENT

11 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY METHODS

11.1 OVERVIEW

11.2 NON-VIRAL METHODS

11.3 VIRAL METHODS

12 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE

12.1 OVERVIEW

12.2 PLASMID DNA

12.3 SMALL INTERFERING RNA (SIRNA)

12.4 PROTEINS

12.5 DNA OLIGONUCLEOTIDES

12.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS)

12.7 OTHERS

13 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM

13.1 OVERVIEW

13.2 MAMMALIAN CELLS

13.3 PLANTS

13.4 FUNGI

13.5 VIRUS

13.6 BACTERIA

14 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY APPLICATION

14.1 OVERVIEW

14.2 IN VITRO APPLICATION

14.2.1 IN VIVO APPLICATION

14.2.2 BIOPRODUCTION

14.2.3 OTHERS

14.2.4 SYNTHETIC BIOLOGY

14.2.5 AGRICULTURE

14.2.6 OTHERS

15 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 BIOPHARMA

15.3 CROS

15.4 CMOS/CDMOS

15.5 ACADEMIA

15.6 HOSPITALS

15.7 CLINICAL LABS

15.8 OTHERS

16 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

16.4 OTHERS

17 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION

17.1 NORTH AMERICA

17.1.1 U.S.

17.1.2 CANADA

17.1.3 MEXICO

18 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 THERMO FISHER SCIENTIFIC INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENT

20.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 PROMEGA CORPORATION

20.3.1 COMPANY SNAPSHOT

20.3.2 COMPANY SHARE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENT

20.4 TAKARA BIO INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENT

20.5 BIO-RAD LABORATORIES, INC.

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANANLYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENT

20.6 ALTOGEN BIOSYSTEMS

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.7 APPLIED BIOLOGICAL MATERIALS INC. (ABM)

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENT

20.1 CYTIVA

20.10.1 COMPANY SNAPSHOT

20.10.2 PRODUCT PORTFOLIO

20.10.3 RECENT DEVELOPMENT

20.11 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)

20.11.1 COMPANY SNAPSHOT

20.11.2 REVENUE ANANLYSIS

20.11.3 PRODUCT PORTFOLIO

20.11.4 RECENT DEVELOPMENT

20.12 GENLANTIS INC.

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 GENO TECHNOLOGY INC., USA

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.14 GINKGO BIOWORKS

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENTS

20.15 LONZA

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANANLYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENT

20.16 MAXCYTE, INC.

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 MERCK KGAA

20.17.1 COMPANY SNAPSHOT

20.17.2 REVENUE ANALYSIS

20.17.3 PRODUCT PORTFOLIO

20.17.4 RECENT DEVELOPMENT

20.18 MIRUS BIO LLC.

20.18.1 COMPANY SNAPSHOT

20.18.2 PRODUCT PORTFOLIO

20.18.3 RECENT DEVELOPMENT

20.19 ORIGENE TECHNOLOGIES, INC.

20.19.1 COMPANY SNAPSHOT

20.19.2 PRODUCT PORTFOLIO

20.19.3 RECENT DEVELOPMENT

20.2 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)

20.20.1 COMPANY SNAPSHOT

20.20.2 REVENUE ANALYSIS

20.20.3 PRODUCT PORTFOLIO

20.20.4 RECENT DEVELOPMENT

20.21 POLYPLUS TRANSFECTION

20.21.1 COMPANY SNAPSHOT

20.21.2 PRODUCT PORTFOLIO

20.21.3 RECENT DEVELOPMENT

20.22 R&D SYSTEMS, INC.

20.22.1 COMPANY SNAPSHOT

20.22.2 PRODUCT PORTFOLIO

20.22.3 RECENT DEVELOPMENT

20.23 SBS GENETECH

20.23.1 COMPANY SNAPSHOT

20.23.2 PRODUCT PORTFOLIO

20.23.3 RECENT DEVELOPMENT

20.24 SIGNAGEN LABORATORIES

20.24.1 COMPANY SNAPSHOT

20.24.2 PRODUCT PORTFOLIO

20.24.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

Lista de Tablas

TABLE 1 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 2 NORTH AMERICA REAGENT AND KITS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 NORTH AMERICA INSTRUMENTS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE, 2021-2030 (USD THOUSAND)

TABLE 5 NORTH AMERICA RESEARCH IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 NORTH AMERICA PRECLINICAL IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 7 NORTH AMERICA CLINICAL PHASES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 NORTH AMERICA COMMERCIAL IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 9 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 NORTH AMERICA TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 NORTH AMERICA STABLE TRANSFECTION REAGENTS AND EQUIPMENT IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 12 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, BY METHODS, 2021-2030 (USD THOUSAND)

TABLE 13 NORTH AMERICA NON-VIRAL METHODS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 14 NORTH AMERICA VIRAL METHODS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 15 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE, 2021-2030 (USD THOUSAND)

TABLE 16 NORTH AMERICA PLASMID DNA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 17 NORTH AMERICA SMALL INTERFERING RNA (SIRNA) IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 NORTH AMERICA PROTEINS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 19 NORTH AMERICA DNA OLIGONUCLEOTIDES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 NORTH AMERICA RIBONUCLEOPROTEIN COMPLEXES (RNPS) IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 NORTH AMERICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM, 2021-2030 (USD THOUSAND)

TABLE 23 NORTH AMERICA MAMMALIAN CELLS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 NORTH AMERICA PLANTS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 NORTH AMERICA FUNGI IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 NORTH AMERICA VIRUS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 27 NORTH AMERICA BACTERIA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET , BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 29 NORTH AMERICA IN VITRO APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 NORTH AMERICA IN VIVO APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 NORTH AMERICA BIOPRODUCTION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 NORTH AMERICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 NORTH AMERICA APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY INDUSTRY, 2021-2030 (USD THOUSAND)

TABLE 34 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 35 NORTH AMERICA BIOPHARMA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 36 NORTH AMERICA CROS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 37 NORTH AMERICA CMOS/CDMOS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 NORTH AMERICA ACADEMIA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 NORTH AMERICA HOSPITALS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 NORTH AMERICA CLINICAL LABS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 NORTH AMERICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 43 NORTH AMERICA DIRECT TENDER IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 44 NORTH AMERICA RETAIL SALES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 NORTH AMERICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

Lista de figuras

FIGURE 1 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 10 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2030

FIGURE 13 THE TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET IN 2022 & 2030

FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET

FIGURE 16 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, 2023

FIGURE 17 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, 2023-2030 (USD THOUSAND)

FIGURE 18 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, CAGR (2023-2030)

FIGURE 19 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, LIFELINE CURVE

FIGURE 20 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, 2023

FIGURE 21 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, 2023-2030 (USD THOUSAND)

FIGURE 22 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 23 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, LIFELINE CURVE

FIGURE 24 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, 2023

FIGURE 25 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 26 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 27 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, 2022

FIGURE 29 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, 2023-2030 (USD THOUSAND)

FIGURE 30 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, CAGR (2023-2030)

FIGURE 31 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, LIFELINE CURVE

FIGURE 32 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, 2022

FIGURE 33 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, 2023-2030 (USD THOUSAND)

FIGURE 34 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, CAGR (2023-2030)

FIGURE 35 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, 2022

FIGURE 37 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, 2023-2030 (USD THOUSAND)

FIGURE 38 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, CAGR (2023-2030)

FIGURE 39 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, LIFELINE CURVE

FIGURE 40 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, 2022

FIGURE 41 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, 2023-2030 (USD THOUSAND)

FIGURE 42 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, CAGR (2023-2030)

FIGURE 43 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, LIFELINE CURVE

FIGURE 44 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY END USER, 2022

FIGURE 45 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 46 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, CAGR (2023-2030)

FIGURE 47 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, LIFELINE CURVE

FIGURE 48 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 49 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 50 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 51 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: SNAPSHOT (2022)

FIGURE 53 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2022)

FIGURE 54 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 55 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 56 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS (2023-2030)

FIGURE 57 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: COMPANY SHARE 2022 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The North America transfection reagent and equipment market size will be worth USD 1,319,255.58 thousand by 2030.
The growth rate of the North America transfection reagent and equipment market is 9.9% during the forecast by 2030.
Rise in the prevalence of chronic diseases & development of synthetic biology products are the growth drivers of the North America transfection reagent and equipment market.
Products, stage, methods, type, types of molecule, application, end user, organism, and distribution channel are the factors on which the North America transfection reagent and equipment market research is based.
Major companies in the North America transfection reagent and equipment market are Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific (A Subsidiary of FUJIFILM Holdings Corporation), Avanti Polar Lipids (A Subsidiary of Croda International Plc), PerkinElmer chemagen Technologie GmbH (A Subsidiary of PerkinElmer Inc.), Cytiva, Geno Technology Inc., USA, R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc. (A Subsidiary of F. Hoffmann-La Roche Ltd), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc. (abm), Beckman Coulter, Inc. (A Subsidiary of Danaher), Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc., and Twist Bioscience, among others.